Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp258 | Osteoporosis: pathophysiology and epidemiology | ECTS2014

Socio-economic status and hip fracture risk: a region-wide ecological study

Reyes Carlen , Javaid M Kassim , Cooper Cyrus , Diez-Perez Adolfo , Prieto-Alhambra Daniel

Purpose: To determine the association between socio-economic status (SES) and risk of hip fracture.Methods: Retrospective cohort study. We used a population database which contains primary care and hospital inpatient records of over >5 million people. Anyone registered in this database in 2009–2012 and resident in an urban area was eligible. Main measures: a validated SES composite index (accounting for proportion of unemployed, insufficiently e...

ba0003pp297 | Osteoporosis: treatment | ECTS2014

Contribution of circulating sclerostin and estradiol for inadequate response to bisphosphonate therapy in women with postmenopausal osteoporosis

Munoz-Torres M , Diez-Perez A , Olmos J M , Nogues X , Sosa M , Diaz-Curiel M , Perez-Castrillon J L , Perez-Cano R , Torrijos A , Jodar E , Rio L Del , Caeiro-Rey J R , Rubio V Avila , Garcia-Martin A , Reyes-Garcia R , Garcia-Fontana B , Gonzalez-Macias J , Morales-Santana S

Bisphosphonate treatment reduces fracture risk in women with postmenopausal osteoporosis. However, some patients have an inadequate response to treatment. Estradiol and sclerostin play an important role in bone metabolism. Sclerostin is an endogenous inhibitor of osteoblastic activity and estrogen deficiency increases osteoclast activity and bone resorption.We examined the influence of both measures on fracture incidence in postmenopausal osteoporosis in...

ba0004p33 | (1) | ICCBH2015

In utero effects of iron status on infant fibroblast growth factor-23 and mineral metabolism

Braithwaite Vickie S , Prentice Ann , Darboe Momodou K , Prentice Andrew M , Moore Sophie E

Fibroblast growth factor-23 (FGF23) is a bone derived phosphate-regulating hormone which is elevated in hypophosphataemic rickets. Recent findings demonstrate iron deficiency as a potential mediator of FGF23 expression and murine studies have shown in utero effects of maternal iron deficiency leading to increased FGF23 concentration and disordered bone development (Clinkenbeard. JBMR 2013). Children with rickets in rural Gambia, West Africa, have high prevalences of i...

ba0005p221b | Chondrocytes and cartilage | ECTS2016

Vitamin D supplementation for 12 months in older people prevents bone loss and suppresses parathyroid hormone levels

Aspray Terry J , Francis Roger M , McColl Elaine , Chadwick Thomas , Stamp Elaine , Prentice Ann , Schoenmakers Inez

Background, subjects and methods: Vitamin D insufficiency in older people in the UK is common and may cause secondary hyperparathyroidism and bone loss. In a randomised, double blind intervention trial to optimise “Vitamin D status in Older People’ (VDOP) three oral dosages of vitamin D3 (12 kIU, 24 kIU or 48 kIU/month) were given for 12 months to 375 participants aged over 70 years (ANOVA) adjustment for covariables with results below presented in ascendi...

ba0005p240 | Genetics and Epigenetics | ECTS2016

Analysis of the polyalanine repeat polymorphism in the RUNX2 gene in relation to bone mineral density and fracture risk in Maltese postmenopausal women

Formosa Melissa M , Sladden Andre J , Scerri Daniel , Xuereb-Anastasi Angela

Introduction: Runt-related transcription factor 2 (RUNX2) is a major transcription factor essential for the regulation of osteoblast and chondrocyte differentiation, hence affecting skeletogenesis, bone and cartilage formation. The RUNX2 protein has unique consecutive polyglutamine and polyalanine repeats (Q/A) which are important for its transactivation function. Several variants within the RUNX2 gene have been implicated in osteoporosis and fracture susceptibility.<...

ba0005p339 | Osteoporosis: pathophysiology and epidemiology | ECTS2016

High prevalence of reduced bone mineral density and undertreatment of osteoporosis in patients with systemic sclerosis

Spanjer Moon J , Bultink Irene E M , Voskuyl Alexandre E , Lems Willem F

Purpose: Systemic sclerosis (SSc) is a rare inflammatory rheumatic disease that has been associated with an increased risk of low bone mineral density (BMD). However, data on risk factors associated with bone loss in SSc are scarce. The objective of this study was to investigate the prevalence of and the risk factors for low BMD in patients with SSc.Methods: Cross-sectional data of 61 patients with SSc were collected. BMD in the lumbar spine, total hip a...

ba0005p472 | Paediatric bone disease | ECTS2016

Osteogenesis imperfecta: clinical and laboratory aspects, about five cases

Nassar Kawtar , Janani Saadia , Rachidi Wafae , Mkinsi Ouafa , Cherqaoui Abdelmounim , Aboumaarouf M

Introduction: Osteogenesis imperfecta is a rare constitutional bone disease. The bone matrix is poor because of the often mutation on the gene coding for collagen I, leading to many fractures. Classification Sillence completed by Glorieux, describes the clinical variability. The management should be done case by case.Study objective: Evaluate the clinical profile, biological and radiological of 5 newly diagnosed cases.Material and ...

ba0006p040 | (1) | ICCBH2017

Atypical femoral fractures in 2 children treated with bisphosphonates

Jacobs Benjamin , Brain Caroline , DeVile Catherine , Allgrove Jeremy , Peeva Daniela , Hashemi-Nejad Aresh , Mughal M Zulf

Background: Atypical Femur Fracture (AFF) has become widely reported as a complication of bisphosphonate therapy in adults since the first case report in 2005. A trend towards a similar pattern of fractures has been reported in children in Sheffield in 2012. A 13 year old boy was reported in 2014 with an ‘AFF’ of the tibia but that fracture did not meet the standard diagnostic criteria of AFF. Last year a 16-year-old girl treated with pamidronate for idiopathic juven...

ba0006p105 | (1) | ICCBH2017

Low serum alkaline phosphatase is often not recognised by clinicians

Moylan Alex , Zulf Mughal M. , Wakeling Emma L. , Peeva Daniela , Jacobs Benjamin

Objective: The significance of low alkaline phosphatase (ALP) is often not recognised by clinicians. It is the hallmark of hypophosphatasia and this oversight leads to delays in diagnosis, inappropriate treatment and potentially harm. Using the standard that an abnormal result should be recognised by the clinician and the potential cause and need for further investigation documented in the medical records we conducted an audit of our practice at the Royal National Orthopaedic ...